CTOs on the Move

Innoviva

www.inva.com

 
Innoviva is a healthcare royalty and asset management company that focuses on maximizing the long-term potential of its royalty portfolio and fueling innovation in areas of significant, often overlooked unmet medical need.
  • Number of Employees: 100-250
  • Annual Revenue: $250-500 Million
  • www.inva.com
  • 35 Gatehouse Drive
    Waltham, MA USA 02451
  • Phone: 650.238.9600

Executives

Name Title Contact Details

Similar Companies

Nautilus Environmental

Nautilus Environmental is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.

Spine Team Texas

Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syndax

Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.

United Home Care Services

United Home Care Services, Inc. is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.